Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01139827|
Recruitment Status : Completed
First Posted : June 9, 2010
Last Update Posted : June 9, 2010
Framingham risk score is well known screening tool that detect cardiovascular (CV) risk. But it is not suitable for CV risk in mild risk group. So 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a new imaging technique for detecting vascular inflammation within atherosclerotic plaques and hsCRP is also arising detection tool of CV risk.
The investigators are examining this association in normal and impaired glucose tolerance patients groups.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||178 participants|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||February 2010|
|Actual Study Completion Date :||February 2010|
normal group has no diabetes.
IGT group has impaired fasting glucose or impaired glucose tolerance.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01139827
|Korea, Republic of|
|Korea university guro hospital|
|Seoul, Korea, Republic of|